Skip to main content
SpringerLink
Log in

Endokrinium und Tumorwachstum

  • Chapter
Klinische Endokrinologie für Frauenärzte

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Akkersdijk GJM, Flu PK, Giard RWM et al. (1990) Malignant leiomyomatosis peritonealis disseminata. Am J Obstet Gynecol 163: 591

    PubMed  Google Scholar 

  • Anderson LF (1991) Cancer act anniversary encourages reflection, new visions. J Natl Cancer Inst 83: 1795

    PubMed  Google Scholar 

  • Atrash HK, Hogue CJR, Grimes DA (1986) Epidemiology of hydatidiform mole during early gestation. Am J Obstet Gynecol 154: 906

    PubMed  Google Scholar 

  • Austin H, Austin JM, Partridge EE et al. (1991) Endometrial cancer, obesity, and body fat distribution. Cancer Res 51: 568

    PubMed  Google Scholar 

  • Bandy LC, Clarke-Pearson DL, Hammond CB (1984) Malignant potential of gestational trophoblastic disease at the extreme ages of reproductive life. Obstet Gynecol 64: 395

    PubMed  Google Scholar 

  • Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet: 104

    Google Scholar 

  • Benagiano G, Morini A, Aleandri V et al. (1990) Sequential buserelin-medroxyprogesterone acetate treatment of leiomyomata uteri. In: Brosens I, Jacobs HS, Runnebaum B (eds) LHRH analogues in gynaecology, Parthenon, Casterton Hall, Carnforth, p 111

    Google Scholar 

  • Beresford SA, Weiss NS, Voigt LF, McKnight B (1997) Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349: 458

    Article  PubMed  Google Scholar 

  • Berger U, Khaghani A, Pomerance A et al. (1990) Pulmonary lymphangioleiomyomatosis and steroid receptors. Am J Clin Pathol 93: 609

    PubMed  Google Scholar 

  • Berkowitz RS, Goldstein DP, Marean AR, Bernstein M (1981) Oral contraceptives and postmolar trophoblastic disease. Obstet Gynecol 58: 474

    PubMed  Google Scholar 

  • Bettendorf U, Bauer KH, Kaiser E (1983) Kasuistischer Beitrag zu hormonellen Aspekten in der Therapie der pulmonalen Lymphangio-Leiomyomatose (LLM). Prax Klin Pneumol 37: 1024

    PubMed  Google Scholar 

  • Blitzer PH, Blitzer EC, Rimm AA (1976) Association between teenage obesity and cancer in 56,111 women: all cancers and endometrial carcinoma. Prev Med 5: 20

    Article  PubMed  Google Scholar 

  • Booth M, Beral V, Smith P (1989) Risk factors for ovarian cancer: a case-control study. Br J Cancer 60: 592

    PubMed  Google Scholar 

  • Bosetti C, Negri E, Franceschi S et al. (2001) Relationship between postmenopausal hormone replacement therapy and ovarian cancer. JAMA 285: 3089

    Article  Google Scholar 

  • Brackertz M (1983) Zur Genetikder Blasenmolen. Geburtshilfe Frauenkeilkd 43: 461

    Google Scholar 

  • Braendle W, Schulz KD (1998) Hormone und Mammakarzinom. Stellungnahme einer Konsensus-Konferenz. In: W Braendle, KD Schulz (Hrsg) Aktuelle Onkologie 100. Hormone und Mammakarzinom. Zuckschwerdt, München Bern Wien New York

    Google Scholar 

  • Brandon DD, Bethea CL, Strawn EY et al. (1993) Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 169: 78

    PubMed  Google Scholar 

  • Brandon DD, Erickson TE, Keenan EJ et al. (1995) Estrogen receptor gene expression in human uterine leiomyomata. J Clin Endocrinol Metab 80: 1876

    Article  PubMed  Google Scholar 

  • Brandt PA, Goldbohm RA, van’t Veer P (1995) Alcohol and breast cancer: results from The Netherlands Cohort Study. Am J Epidemiol 141: 907

    PubMed  Google Scholar 

  • Brinton LA, Berman ML, Mortel R et al. (1992) Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 167: 1317

    PubMed  Google Scholar 

  • Bush TL, Whiteman M, Flaws JA (2001) Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 98: 498

    Article  PubMed  Google Scholar 

  • Byrne C, Schairer C, Wolfe J et al. (1995) Mammographic features and breast cancer risk: effects with time, age, and menopause Status. J Natl Cancer Inst 87: 1622

    PubMed  Google Scholar 

  • Cauley JA, Lucas FL, Kuller LH et al. (1999) Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med 130: 270

    PubMed  Google Scholar 

  • Chaudhuri PK, Walker MK, Briele HA et al. (1980) Incidence of estrogen receptor in benign nevi and human malignant melanoma. JAMA 244: 791

    Article  PubMed  Google Scholar 

  • Chlebowski RT, McTiernan A (1999) Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer. J Clin Oncol 17: 130

    PubMed  Google Scholar 

  • Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344: 276

    Article  PubMed  Google Scholar 

  • Col NF, Hirota LK, Orr RK et al. (2001) Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 19: 2357

    PubMed  Google Scholar 

  • Colditz GA, Rosner B (1998) Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone. Am J Epidemiol 147[Suppl]: 645

    Google Scholar 

  • Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713

    Google Scholar 

  • Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350: 1047

    Google Scholar 

  • Covens A, Thomas G, Shaw P et al. (1997) A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol Oncol 64: 126

    Article  PubMed  Google Scholar 

  • Cunanan RG, Lippes J, Tancinco PA (1980) Choriocarcinoma of the ovary with coexisting normal pregnancy. Obstet Gynecol 55: 669

    PubMed  Google Scholar 

  • Dougherty CM, Cunningham C, Mickal A (1978) Choriocarcinoma with metastasis in a postmenopausal woman. Am J Obstet Gynecol 132: 700

    PubMed  Google Scholar 

  • Early Breast Cancer Trialists‘ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451

    Google Scholar 

  • Eddy GL, Schlaerth JB, Nalick RH et al. (1983) Postmolar trophoblastic disease in women using hormonal contraception with and without estrogen. Obstet Gynecol 62: 736

    PubMed  Google Scholar 

  • Eeles RA, Tan S, Wiltshaw E et al. (1991) Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 302: 259

    PubMed  Google Scholar 

  • Ehrlich CE, Young PC, Cleary RE (1981) Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications. Am J Obstet Gynecol 141: 539

    PubMed  Google Scholar 

  • Eiermann W, Luderschmidt C, Burgkart A et al. (1985) Steroidrezeptoren bei malignen Melanomen. Hautarzt 36: 393

    PubMed  Google Scholar 

  • Elwood JM, Cole P, Rothman KJ, Kaplan SD (1977) Epidemiology of endometrial cancer. J Natl Cancer Inst 59: 1055

    PubMed  Google Scholar 

  • Emons G, Ortmann O, Pahwa GS et al. (1992) In-vivo-und In-vitro-Effekte von GnRH-Analoga auf einen ovariellen Leydigzelltumor. Geburtshilfe Frauenheilkd 52: 487

    PubMed  Google Scholar 

  • Emons G, Schroder B, Ortmann O et al. (1993) High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 77: 1458

    Article  PubMed  Google Scholar 

  • Farhi DC, Nosanchuk J, Silverberg SG (1986) Endometrial adenocarcinoma in women under 25 years of age. Obstet Gynecol 68: 741

    PubMed  Google Scholar 

  • Feig SA (1996) Assessment of radiation risk from screening mammography. Cancer 77: 818

    Article  PubMed  Google Scholar 

  • Ferenczy A, Gelfand M (1989) The biologic significance of Cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 160: 126

    PubMed  Google Scholar 

  • Fisher B, Costantino JP, Redmond CK et al. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86: 527

    PubMed  Google Scholar 

  • Fisher B (1996a) Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients. J Clin Oncol 14: 1027

    PubMed  Google Scholar 

  • Fisher B, Dignam J, Bryant J et al. (1996b) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88: 1529

    PubMed  Google Scholar 

  • Fisher B, Costantino JP, Wickerham DL et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371

    PubMed  Google Scholar 

  • Folsom AR, Kaye SA, Potter JD, Prineas RJ (1989) Association of incident carcinoma of the endometrium with body weight and fat distribution in older women: early findings of the Iowa Women’s Health Study. Cancer Res 49: 6828

    PubMed  Google Scholar 

  • Fornander T, Rutqvist LE, Cedermark B et al. (1989) Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1: 117

    Article  PubMed  Google Scholar 

  • Fornander T, Hellstrom AC, Moberger B (1993) Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 85: 1850

    PubMed  Google Scholar 

  • Franceschi S, La Vecchia C, Negri E et al. (1994) Fertility drugs and risk of epithelial ovarian cancer in Italy. Hum Reprod 9: 1673

    PubMed  Google Scholar 

  • Franchi M, Grezzi F, Donadello N et al. (1999) Endometrial thickness in tamoxifen-treated patients: an independent predictor of endometrial disease. Obstet Gynecol 93: 1004

    Article  PubMed  Google Scholar 

  • Freeman DA (1986) Steroid hormone-producing tumors in man. Endocr Rev 7: 204

    PubMed  Google Scholar 

  • Friedman AJ, Lobel SM, Rein MS, Barbieri RL (1990) Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis. Am J Obstet Gynecol 163: 1114

    PubMed  Google Scholar 

  • Friedman AJ (1995) Treatment of uterine leiomyomas with gonadotropin-releasing hormone agonists. Endocrinologist 5: 61

    Google Scholar 

  • Friedmann W, Chmielewski G, Minguillon C et al. (1992) Disseminierte Lymphangioleiomyomatose. Geburtshilfe Frauenheilkd 52: 175

    PubMed  Google Scholar 

  • Gallagher CJ, Oliver RT, Oram DH et al. (1991) A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue. Br J Obstet Gynaecol 98: 1037

    PubMed  Google Scholar 

  • Garg PP, Kerlikowske K, Subak L, Grady D (1998) Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 92: 472

    Article  PubMed  Google Scholar 

  • Gerhardsson de Verdier M, London S (1992) Reproductive factors, exogenous female hormones, and colorectal cancer by subsite. Cancer Causes Control 3: 355

    Article  PubMed  Google Scholar 

  • Gesenhues T, Hackenberg R, Deichert U et al. (1989) Neue Möglichkeiten zur differenzierten Therapie von Leiomyomen des Uterus mit dem GnRH-Agonisten «Zoladex“. Geburtshilfe Frauenheilkd 49: 96

    PubMed  Google Scholar 

  • Givens JR, Andersen RN, Wiser WL et al. (1975) A testosterone-secreting, gonadotropin-responsive pure thecoma and polycystic ovarian disease. JClin Endocrinol Metab 41: 845

    Google Scholar 

  • Goldstein DP, Berkowitz RS (1982) Gestational trophoblastic neoplasms. WB Saunders, Philadelphia

    Google Scholar 

  • Goodman MT, Hankin JH, Wilkens LR et al. (1997) Diet, body size, physical activity, and the risk of endometrial cancer. Cancer Res 57: 5077

    PubMed  Google Scholar 

  • Grady D, Gebretsadik T, Kerlikowske K et al. (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85: 304

    Article  PubMed  Google Scholar 

  • Graf M, Krüssel JS, Conrad M et al. (1995) Zur Rückbildung funktioneller Zysten: Hochdosierte Ovulationshemmer und Gestagentherapie ohne zusätzlichen Effekt. Geburtshilfe Frauenheilkd 55: 387

    PubMed  Google Scholar 

  • Greendale GA, Reboussin BA, Sie A et al. (1999) Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 130:262

    PubMed  Google Scholar 

  • Grimes DA. (1984) Epidemiology of gestational trophoblastic disease. Am J Obstet Gynecol 150: 309

    PubMed  Google Scholar 

  • Gross TP, Schlesselman JJ (1994) The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol 83: 419

    PubMed  Google Scholar 

  • Guidozzi F, Daponte A (1999) Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer 86: 1013

    Article  PubMed  Google Scholar 

  • Hales HA, Peterson CM, Jones KP, Quinn JD (1992) Leiomyomatosis peritonealis disseminata treated with a gonadotropin-releasing hormone agonist. Am J Obstet Gynecol 167: 515

    PubMed  Google Scholar 

  • Haning RV, Loughlin J, Shapiro SS (1989) Diagnosis and resection of an oral contraceptive-suppressible Sertoli-Leydig cell tumor with preservation of fertility and a 7-year follow-up. Obstet Gynecol 73: 901

    PubMed  Google Scholar 

  • Hankinson SE, Colditz GA, Hunter DJ et al. (1992) A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 80: 708

    PubMed  Google Scholar 

  • Hankinson SE, Colditz GA, Hunter DJ et al. (1995) A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 76: 284

    PubMed  Google Scholar 

  • Harris R, Whittemore AS, Intyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 136:1204

    PubMed  Google Scholar 

  • Harrison RA, Waterbor JW (1999) Understanding meta-analysis in cancer epidemiology: dietary fat and breast cancer. Cancer Detect Prev 23: 97

    Article  PubMed  Google Scholar 

  • Harrison-Woolrych M, Robinson R (1995) Fibroid growth in response to high-dose progestogen. Fertil Steril 64: 191

    PubMed  Google Scholar 

  • Henderson BE, Casagrande JT, Pike MC et al. (1983) The epidemiology of endometrial cancer in young women. Br J Cancer 47: 749

    PubMed  Google Scholar 

  • Holmes MD, Hunter DJ, Colditz GA et al. (1999) Association of dietary intake of fat and fatty acids with risk of breast cancer. JAMA 281: 914

    Article  PubMed  Google Scholar 

  • Howe GR, Hirohata T, Hislop TG et al. (1990) Dietary factors and risk of breast cancer: combined analysis of 12 case-control studies. J Natl Cancer Inst 82: 561

    PubMed  Google Scholar 

  • Huang Z, Hankinson SE, Colditz GA et al. (1997) Dual effects of weight and weight gain on breast cancer risk. JAMA 278: 1407

    Article  PubMed  Google Scholar 

  • Huang CS, Chern HD, Chang KJ et al. (1999) Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 59: 4870

    PubMed  Google Scholar 

  • Hunter DJ, Spiegelman D, Adami HO et al. (1996) Cohort studies of fat intake and the risk of breast cancer-a pooled analysis. N Engl J Med 334: 356

    Article  PubMed  Google Scholar 

  • Hutchison JR, Peterson EP, Zimmermann EA (1968) Coexisting metastatic choriocarcinoma and normal pregnancy. Obstet Gynecol 31: 331

    PubMed  Google Scholar 

  • Jacobs PA, Hunt PA, Matsuura JS, Wilson CC (1982) Complete and partial hydatidiform mole in Hawaii: cytogenetics, morphology and epidemiology. Br J Obstet Gynaecol 89: 258

    PubMed  Google Scholar 

  • Jick SS, Walker AM, Jick H (1993) Oral contraceptives and endometrial cancer. Obstet Gynecol 82: 931

    PubMed  Google Scholar 

  • Käser O, Castaño-Almendral A (1977) Die gestationsbedingten Trophoblasterkrankungen (GTE). Gynäkologe 10: 190

    Google Scholar 

  • Kajii T, Kurashige H, Ohama K, Uchino F (1984) XY and XX complete moles: Clinical and morphologic correlations. Am J Obstet Gynecol 150: 57

    PubMed  Google Scholar 

  • Kampman E, Bijl AJ, Kok C, van’t Veer P (1994) Reproductive and hormonal factors in male and female colon cancer. Europ J Cancer Prevention 3: 329

    Google Scholar 

  • Kang J, Baxi L, Heller D (1996) Tamoxifen-induced growth of leiomyomas. J Reprod Med 41: 119

    PubMed  Google Scholar 

  • Keifer WS, Scott JC (1977) Liver neoplasms and the oral contraceptives. Am J Obstet Gynecol 128: 448

    PubMed  Google Scholar 

  • Kelsey JL (1979) A review of the epidemiology of human breast cancer. Epidemiol Rev: 174

    Google Scholar 

  • Kelsey JL, Li Volsi VA, Holford TR et al. (1982) A case-control study of cancer of the endometrium. Am J Epidemiol 116: 333–342

    PubMed  Google Scholar 

  • Kettel LM, Rivier J, Murphy AM et al. (1993) Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil Steril 60: 642

    PubMed  Google Scholar 

  • Kimya Y, Cengiz C, Tolunay S (1994) Endometrial polyps, cystic glandular hyperplasia and atypical leiomyoma associated with tamoxifen therapy. Int J Gynecol Obstet 46: 94

    Article  Google Scholar 

  • Kline RC, Freedman RS, Jones LA (1987) Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate. Cancer Treat Rep 71: 327

    PubMed  Google Scholar 

  • Korpela JT, Adlercreutz H, Turunen MJ (1988) Fecal free and conjugated bile acids and neutral sterols in vegetarians, omnivores, and patients with colorectal cancer. Scand J Gastroenterol 23: 277

    PubMed  Google Scholar 

  • Krämer U, Schulte KW, Schürer NY, Schuppe HC (1994) Das maligne Melanom unter besonderer Berücksichtigung der Aspekte in der Frauenheilkunde. Gynäkologe 27: 321

    PubMed  Google Scholar 

  • La Vecchia C, Franceschi S, Fasoli M, Mangioni C (1982) Gestational trophoblastic neoplasms in homozygous twins. Obstet Gynecol 60: 250

    PubMed  Google Scholar 

  • Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999. CA Cancer J Clin 49: 8

    Google Scholar 

  • Landthaler M, Braun-Falco O (1985) Maligne Melanome in der Schwangerschaft. Dtsch Med Wochenschr 110: 1319

    PubMed  Google Scholar 

  • Laya MB, Larson EB, Taplin SH, White E (1996) Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst 88: 643

    PubMed  Google Scholar 

  • LevGur M, Levie MD (1995) The myomatous erythrocytosis syndrome: a review. Obstet Gynecol 86: 1026

    Article  PubMed  Google Scholar 

  • Li HW, Tsao SW, Cheung AN (2002) Current understandings of the molecular genetics of gestational trophoblastic diseases. Placenta (England) 23: 20

    Article  PubMed  Google Scholar 

  • Levi F, La Vecchia C, Negri E et al. (1992) Body mass at different ages and subsequent endometrial cancer risk. Int J Cancer 50: 567

    PubMed  Google Scholar 

  • Litherland JC, Stallard S, Hole D, Cordiner C (1999) The effect of hormone replacement therapy on the sensitivity of screening mammograms. Clin Radiol 54: 285

    Article  PubMed  Google Scholar 

  • London SJ, Colditz GA, Stampfer MJ et al. (1989) Prospective study of smoking and the risk of breast cancer. J Natl Cancer Inst 81: 1625

    PubMed  Google Scholar 

  • Lundstrom E, Wilczek B, von Palffy Z et al. (1999) Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 181: 348

    PubMed  Google Scholar 

  • MacKie RM, Bufalino R, Morabito A et al. (1991) Lack of effect of pregnancy on outcome of melanoma. Lancet 337: 653

    Article  PubMed  Google Scholar 

  • MacMahon B (1974) Risk factors for endometrial cancer. Gynecol Oncol 2: 122

    Article  PubMed  Google Scholar 

  • Magnusson C, Baron JA, Correia N et al. (1999) Breast-cancer risk following long-term oestrogen-and oestrogen-progestin-replacement therapy. Int J Cancer 81: 339

    Article  PubMed  Google Scholar 

  • Malmström H, Högberg T, Risberg B, Simonsen E (1994) Granulosa cell tumors of the ovary: prognostic factors and outcome. Gynecol Oncol 52: 50

    Article  PubMed  Google Scholar 

  • Mant JW, Vessey MP (1994) Ovarian and endometrial cancers. Cancer Surv 287: 19–20

    Google Scholar 

  • Mays ET, Christopherson W (1984) Hepatic tumors induced by sex steroids. Sem Liv Dis 4: 147

    Google Scholar 

  • McMichael AJ, Potter JD (1980) Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. JNCI 65: 1201

    PubMed  Google Scholar 

  • Mestwerdt W (1988) Gutartige Erkrankungen des Corpus uteri. In: Wulf KH, Schmidt-Matthiesen H (Hrsg) Klinik der Frauenheilkunde und Geburtshilfe Bd 8, Gutartige gynäkologische Erkrankungen I. Urban & Schwarzenberg, München Wien Baltimore, S 159

    Google Scholar 

  • Miller AB, Howe GR, Sherman GJ et al. (1989) Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis. N Engl J Med 321: 1285

    PubMed  Google Scholar 

  • Milligen van de Wit AWM, Meilof-Planteydt MNM (1990) Successful treatment of pulmonary lymphangioleiomyomatosis with oophorectomy and medroxyprogesterone-acetate: report of a case and brief review of the literature. Neth J Med 36: 246

    PubMed  Google Scholar 

  • Millward MJ, Cantwell BMJ (1991) Development of breast cancer during long-term tamoxifen therapy for lymphangioleiomyomatosis. Eur J Cancer 27: 806

    Google Scholar 

  • Minassian SS, Frangipane W, Polin Jl, Ellis M (1986) Leiomyomatosis peritonealis disseminata — a case report and literature review. J Reprod Med 31: 997

    PubMed  Google Scholar 

  • Modan B, Hartge P, Hirsh-Yechezkel G et al. (2001) Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345

    Google Scholar 

  • Moore TD, Phillips PH, Nerenstone SR, Cheson BD (1991) Systemic treatment of advanced and recurrent endometrial carcinoma: current Status and future directions. J Clin Oncol 9: 1071

    PubMed  Google Scholar 

  • Morrow P, Nakamura R, Schlaerth J et al. (1985) The influence of oral contraceptives on the postmolar human chorionic gonadotropin regression curve. Am J Obstet Gynecol 151: 906

    PubMed  Google Scholar 

  • Mosgaard BJ, Lidegaard O, Andersen AN (1997a) The impact of parity, infertility and treatment with fertility drugs on the risk of ovarian cancer. A survey. Acta Obstet Gynecol Scand 76: 89–95

    Google Scholar 

  • Mosgaard BJ, Lidegaard O, Kjaer SK et al. (1997b) Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril 67: 1005

    Article  PubMed  Google Scholar 

  • Murphy AA, Morales AJ, Kettel LM, Yen SSC (1995) Regression of uterine leiomyomata to the antiprogesterone RU 486: dose-response effect. Fertil Steril 64: 187

    PubMed  Google Scholar 

  • Nagamani M, Stuart CA (1992) Specific binding sites for insulin in the human myometrium and leiomyomas of the Uterus. Fertil Steril 58: 120

    PubMed  Google Scholar 

  • Narod SA, Risch H, Moslehi R et al. (1998) Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339: 424

    Article  PubMed  Google Scholar 

  • Neifeld JP, Lippman ME (1980) Steroid hormone receptors and melanoma. J Invest Dermatol 74: 379

    Article  PubMed  Google Scholar 

  • Novak ER, Kutchmeshgi J, Mupas RS, Woodruff JD (1971) Feminizing gonadal stromal tumors. Obstet Gynecol 38: 701

    PubMed  Google Scholar 

  • Ohori NP, Yousem SA, Sonmez-Alpan E, Colby TC (1991) Estrogen and progesterone receptors in lymphangioleiomyomatosis, epitheloid hemangioendothelioma, and sclerosing hemangioma of the lung. Am J Clin Pathol 96: 529

    PubMed  Google Scholar 

  • Olive DL, Lurain JR, Brewer Jl (1984) Choriocarcinoma associated with term gestation. Am J Obstet Gynecol 148: 711

    PubMed  Google Scholar 

  • Olson SH, Trevisan M, Marshall JR et al. (1995) Body mass index, weight gain, and risk of endometrial cancer. Nutr Cancer 23: 141

    PubMed  Google Scholar 

  • Ortmann O, Strowitzki T, Diedrich K (1999) Tibolon in der postmenopausalen Hormonsubstitution: Gewebespezifische Metabolisierung als Therapieprinzip. Frauenarzt 40: 523

    Google Scholar 

  • Ortmann O, Schulz KD, Diedrich K (2000) Hormonersatztherapie in der Postmenopause und Mammakarzinomrisiko. Gynäkologe 33: 402

    Google Scholar 

  • Osmers R, Völksen M, Hinney B et al. (1990) Klinisches Management von zystischen Ovarialtumoren. Geburtshilfe Frauenheilkd 50: 20

    PubMed  Google Scholar 

  • Østerlind A (1992) Hormonal and reproductive factors in melanoma risk. Clinics Dermatol 10: 75

    Article  Google Scholar 

  • Parazzini F, La Vecchia C, Franceschi S, Mangili G (1984) Familial trophoblastic disease: case report. Am J Obstet Gynecol 149: 382

    PubMed  Google Scholar 

  • Parazzini F, Moroni S, La Vecchia C et al. (1997a) Ovarian cancer risk and history of selected medical conditions linked with female hormones. Eur J Cancer 33: 1634

    Article  PubMed  Google Scholar 

  • Parazzini F, Negri E, La Vecchia C et al. (1997b) Treatment for infertility and risk of invasive epithelial ovarian cancer. Hum Reprod 12: 2159

    Article  PubMed  Google Scholar 

  • Parkin DM, Pisani P, Ferlay J (1999) Global cancer statistics. CA Cancer J Clin 49: 33

    Google Scholar 

  • Pasqualini JR, Vella C, Cornier E et al. (1990) Effect of decapeptyl, an agonistic analog of gonadotropin-releasing hormone on estrogens, estrogen Sulfates, and progesterone receptors in leiomyoma and myometrium. Fertil Steril 53: 1012

    PubMed  Google Scholar 

  • Pastorfide GB, Goldstein DP (1973) Pregnancy following hydatidiform mole. Obstet Gynecol 42: 67

    PubMed  Google Scholar 

  • Pathak DR, Whittemore AS (1992) Combined effects of body size, parity, and menstrual events on breast cancer incidence in seven countries. Am J Epidemiol 135: 153

    PubMed  Google Scholar 

  • Persson I, Thurfjell E, Holmberg L (1997) Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol 15: 3201

    PubMed  Google Scholar 

  • Pfleiderer A (1986a) Die Diagnostik des Ovarialkarzinoms. Gynäkologe 19: 142

    PubMed  Google Scholar 

  • Pfleiderer A (1986b) Maligne Tumoren der Ovarien. Enke, Stuttgart

    Google Scholar 

  • Pfleiderer A (1989) Malignome des Ovars. In: Schmidt-Matthiesen H (Hrsg) Spezielle gynäkologische Onkologie II. Urban & Schwarzenberg, München Wien Baltimore, S 45

    Google Scholar 

  • Piver MS, Barlow JJ, Lurain JR, Blumenson LE (1980) Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer 45: 268

    PubMed  Google Scholar 

  • Pike MC, Peters RK, Cozen W et al. (1997) Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 89: 1110

    Article  PubMed  Google Scholar 

  • Podczaski ES, Satyaswaroop PG, Mortel R (2000) Hormonal interactions in gynecologic malignancies. In: WJ Hoskins, CA Perez, RC Young (eds) Principles and practice of gynecolgic oncology, 3rd edn. Lippincott, Williams & Wilkins, Philadelphia

    Google Scholar 

  • Potischman N, Swanson CA, Brinton LA et al. (1993) Dietary associations in a case-control study of endometrial cancer. Cancer Causes Control 4: 239

    PubMed  Google Scholar 

  • Powles T, Eeles R, Ashley S et al. (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352: 98

    PubMed  Google Scholar 

  • Purdie DM, Bain CJ, Siskind V et al. (1999) Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 81: 559

    Article  PubMed  Google Scholar 

  • Rabe T, Leppien G, Runnebaum B (1987) Hormonaktive Ovarialtumoren. In: Runnebaum B, Rabe T (Hrsg) Gynäkologische Endokrinologie. Springer, Berlin Heidelberg New York Tokyo, S 625

    Google Scholar 

  • Randall TC, Kurman RJ (1997) Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 90: 434

    Article  PubMed  Google Scholar 

  • Risch HA, Marrett LD, Howe GR (1994) Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 140: 585

    PubMed  Google Scholar 

  • Rodriguez C, Patel AV, Calle EE et al. (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285: 1460

    Article  PubMed  Google Scholar 

  • Ron E, Lunenfeld B, Menczer J et al. (1987) Cancer incidence in a cohort of infertile women. Am J Epidemiol 125: 780

    PubMed  Google Scholar 

  • Rose GS, Carlson JW, Birrer MJ (2000) Basic biology and biochemistry of gynecologic cancer. In: Hoskins WJ, Perez CA, Young RC (eds) Principles and practice of gynecologic oncology, 3rd edn. Lippincott, Williams & Wilkins, Philadelphia

    Google Scholar 

  • Rosenberg L, Palmer JR, Zauber AG et al. (1994) A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 139: 654

    PubMed  Google Scholar 

  • Rossi GA, Balbi B, Oddera S, Lantero S, Ravazzoni C (1991) Response to treatment with an analog of the luteinizing-hormone-releasing hormone in a patient with pulmonary lymphangioleiomyomatosis. Am Rev Respir Dis 143: 174

    PubMed  Google Scholar 

  • Rossing MA, Daling JR, Weiss NS et al. (1994) Ovarian tumors in a cohort of infertile women. N Engl J Med 331: 771

    Article  PubMed  Google Scholar 

  • Ryden S, Ferno M, Moller T et al. (1992) Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial. Acta Oncol 31: 271

    Google Scholar 

  • Santen RJ, Pinkerton J, McCartney C, Petroni GR (2001) Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab 86: 16

    Article  PubMed  Google Scholar 

  • Schairer C, Lubin J, Troisi R et al. (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283: 485

    Article  PubMed  Google Scholar 

  • Schlesselman JJ (1991) Oral contraceptives and neoplasia of the uterine corpus. Contraception 43: 557

    Article  PubMed  Google Scholar 

  • Schoultz vonB, Söderquist G, Cline JM (1998) Möglichkeiten der Hormonsubstitution: zyklische Therapie. In: Römer T, Mueck OA (Hrsg) Endometrium und Hormonsubstitution. Thieme, Stuttgart New York, S 95

    Google Scholar 

  • Schultze-Mosgau A, Koshimizu T, Katzur AC et al. (2000) Expression and coupling of P2Y2 receptors in human ovarian cancer cells. Mol Hum Reprod 6: 435

    Article  PubMed  Google Scholar 

  • Schultze-Mosgau A, Ortmann O, Diedrich K (2002) Wirkungen von Tamoxifen auf das Endometrium. Geburtshilfe Frauenheilkd 62: 743

    Article  Google Scholar 

  • Schwartz LB, Lazer S, Mark M et al. (1996) Does the use of postmenopausal hormone replacement therapy influence the size of uterine leiomyomata? A preliminary report. N Am Menopause Soc 3: 38

    Google Scholar 

  • Sener AB, Gökmen O, Seckin NS et al. (1996) The effects of hormone replacement therapy on uterine fibroids in postmenopausal woman. Fertil Steril 65: 354

    PubMed  Google Scholar 

  • Serra GB, Villani L, Panici PB (1983) Ovarian tumors. In: Serra GB (ed) The ovary, Raven, New York, p 391

    Google Scholar 

  • Shen A, Iseman MD, Waldron JA, King TE (1987) Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous estrogens. Chest 91: 782

    PubMed  Google Scholar 

  • Shiu MH, Schottenfeld D, Mclean B, Fortner JC (1976) Adverse effect of pregnancy on melanoma. Cancer 37: 181

    PubMed  Google Scholar 

  • Shoff SM, Newcomb PA (1998) Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol 148: 234

    PubMed  Google Scholar 

  • Shu XO, Brinton LA, Zheng W (1992) Relation of obesity and body fat distribution to endometrial cancer in Shanghai, China. Cancer Res 52: 3865

    PubMed  Google Scholar 

  • Shushan A, Paltiel O, Iscovich J (1996) Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 65: 13

    PubMed  Google Scholar 

  • Slamon DJ, Leyland Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783

    Article  PubMed  Google Scholar 

  • Speroff L (2000) The estrogen receptor: changing concepts. Climacteric 3: 2

    Google Scholar 

  • Smith SK (1993) The regulation of fibroid growth: time for a re-think? Brit J Obstet Gynaecol 100: 977

    Google Scholar 

  • Stegner HE (1985) Geschwülste der Adnexe. In: Käser O, Friedberg V, Ober KG, Thomsen K, Zander J (Hrsg) Gynäkologie und Geburtshilfe. Thieme, Stuttgart New York, Kap. 10.2

    Google Scholar 

  • Steinkampf MP, Hammond KR, Blackwell RE (1990) Hormonal treatment of functional ovarian cysts: a randomized, prospective study. Fertil Steril 54: 775

    PubMed  Google Scholar 

  • Steller MA, Goldstein DP, Berkowitz RS (1993) Endocrine aspects of gestational trophoblastic disease. Endocrinologist 3: 136

    Google Scholar 

  • Swanson CA, Potischman N, Wilbanks GD et al. (1993) Relation of endometrial cancer risk to past and contemporary body size and body fat distribution. Cancer Epidemiol Biomarkers Prev 2: 321

    PubMed  Google Scholar 

  • Tham KF, Ratnam SS (1995) Current views on the management of trophoblostic tumors. Int J Gynecol Obstet 49[Suppl]: 77

    Article  Google Scholar 

  • The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development (1987a) Combination oral contraceptive use and the risk of endometrial cancer. JAMA 257: 796

    Google Scholar 

  • The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development (1987b) The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med 316: 650

    Google Scholar 

  • Thiel van D, Ross GT, Lipsett MB (1970) Pregnancies after chemotherapy for trophoblastic neoplasms. Science 169: 1326

    PubMed  Google Scholar 

  • Toniolo PG, Levitz M, Zeleniuch-Jacquotte A et al. (1995) A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 87: 190

    PubMed  Google Scholar 

  • Townsend DE, Sparkes RS, Baluda MC, Mc Chelland G (1970) Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis of glucose-6-phosphate dehydrogenase. Am J Obstet Gynecol 107: 1168

    PubMed  Google Scholar 

  • Tscherne G (1987) Trophoblasttumor: Diagnostik, Therapie und Nachsorge. Speculum 5: 3

    Google Scholar 

  • Vana J, Murphy GP, Aronoff BL, Baker HW (1977) Primary liver tumors and oral contraceptives. JAMA 238: 2154

    Article  PubMed  Google Scholar 

  • Vessey MP, Painter R (1995) Endometrial and ovarian cancer and oral contraceptives — findings in a large cohort study. Br J Cancer 71: 1340

    PubMed  Google Scholar 

  • Walden PAM, Bagshawe KD (1976) Reproductive Performance of women successfully treated for gestational trophoblastic tumors. Am J Obstet Gynecol 125: 1108

    PubMed  Google Scholar 

  • Weiderpass E, Adami HO, Baron JA et al. (1999) Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 91: 1131

    Article  PubMed  Google Scholar 

  • Weiss NS, Szekely DR, Austin DF (1976) Increasing incidence of endometrial cancer in the United States. N Engl J Med 294: 1259

    PubMed  Google Scholar 

  • Writing group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women’s Health initiative randomised controlled trail. JAMA 288: 321–333

    Google Scholar 

  • Whittemore AS, Harris R, Intyre J (1992a) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 136: 1184

    PubMed  Google Scholar 

  • Whittemore AS, Harris R, Intyre J (1992b) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 136: 1212

    PubMed  Google Scholar 

  • Wilhelm C, Quaas L, Zahradnik HP, Breckwoldt M (1990) Durch orale Kontrazeptiva induzierte Lebertumoren und Schwangerschaft. Geburtshilfe Frauenheilkd 50: 806

    PubMed  Google Scholar 

  • Willett WC (2001) Diet and breast cancer. J Intern Med 249: 395

    Article  PubMed  Google Scholar 

  • Willett WC, Rockhill B, Hankinson SE et al. (2000) Epidemiology and nongenetic causes of breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the breast, 2nd edn. Lippincott, Williams & Wilkins, Philadelphia

    Google Scholar 

  • Wobbes T, Beex LVAM, Koenders AMJ (1984) Estrogen and progestin receptors in colonic cancer? Dis Colon Rectum 27: 591

    PubMed  Google Scholar 

  • Wu AH, Pike MC, Stram DO (1999) Meta-analysis: dietary fat intake, serum estrogen levels, and the risk of breast cancer. J Natl Cancer Inst 91: 529

    Article  PubMed  Google Scholar 

  • Wu ML, Whittemore AS, Paffenbarger RS et al. (1988) Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol 128: 1216

    PubMed  Google Scholar 

  • Yuen BH, Burch P (1983) Relationship of oral contraceptives and the intrauterine contraceptive devices to the regression of concentrations of the beta subunit of human chorionic gonadotropin and invasive complications after molar pregnancy. Am J Obstet Gynecol 145: 214

    PubMed  Google Scholar 

  • Ziegler RG, Hoover RN, Nomura AM (1996) Relative weight, weight change, height, and breast cancer risk in Asian-American women. J Natl Cancer Inst 88: 650

    PubMed  Google Scholar 

Download references

Authors
  1. O. Ortmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lokstedter Damm 15, 22453, Hamburg

    Freimut Leidenberger

  2. Abt. Gynäkologische Endokrinologie und Fertilitätsstörungen, Universitätsfrauenklinik Heidelberg, Voßstraße 9, 69115, Heidelberg

    Thomas Strowitzki

  3. Klinik für Frauenheilkunde und Geburtshilfe der Universität Regensburg am Caritas Krankenhaus St. Josef, Landshuter Straße 65, 93053, Regensburg

    Olaf Ortmann

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Ortmann, O. (2005). Endokrinium und Tumorwachstum. In: Leidenberger, F., Strowitzki, T., Ortmann, O. (eds) Klinische Endokrinologie für Frauenärzte. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26406-X_22

Download citation

  • DOI: https://doi.org/10.1007/3-540-26406-X_22

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-44162-5

  • Online ISBN: 978-3-540-26406-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation